Summary Safety Review - Denosumab (Prolia and Xgeva) - Hearing loss and deafness (English, HTML)
Summary Safety Review - Denosumab (Prolia and Xgeva) - Hearing loss and deafness: English HTML file. From Health Canada, updated May 2024. View metadata, licence and the direct download on CanQuery.
- Format
- HTML
- Access
- Original download only
- Publisher-reported update
- 2024-05-08
A safety review was carried out after Health Canada received a report from the European Medicines Agency, which linked hearing loss and deafness to the use of Prolia and Xgeva. After review of the report, Health Canada determined that there is not enough information to make such a link. The risk of hearing loss or deafness is already listed in the prescribing information for Xgeva (less common side effect for people with advanced bone cancer), but not for Prolia.
Data overview
- Formats
- HTML
- File languages
- English
- Available actions
- Access original file